ReviewMaterials today. Bio2025
Radionuclide-labeled nanomaterials for tumor therapy: Recent progress and perspectives.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Linking In Vivo Imaging to Therapeutic Outcome withInternational journal of molecular sciences · 2026Review
- The Application of Radiolabeled Mesoporous Silica Nanoparticles in Molecular Imaging.Molecules (Basel, Switzerland) · 2026Review
- Auto-loaded polydopamine-M2 exosomes as an antioxidative nanoscavenger for lupus erythematosus therapy.Materials today. Bio · 2026Article
- NIS-Centered Reporter Gene Imaging and Radionuclide-Integrated Nanoplatforms for Quantitative Tracking of Immune Cell Therapy in Oncology and Inflammatory Disease Models.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radionuclide therapy (RNT) uses the ionizing radiation generated by the emitted particles during radioactive decay to directly damage DNA structure or indirectly increase the concentration of free radicals in cells, thereby destroying or killing diseased cells. Radionuclides offer the advantages of high sensitivity, non-invasive, and functional imaging in clinical diagnosis. The key to RNT is to deliver sufficient radiation dose to tumors while reducing toxic side effects on normal tissues and organs. However, most radionuclides are unable to reach the lesion site, and the radiation dose is not sufficient to completely kill cancer cells. In recent years, the rapid development of nanotechnology has provided new ideas for the design of radiopharmaceuticals. Compared to small molecules, nanomaterials have the advantages of a larger specific surface area, more labeling sites, good biocompatibility, and a longer blood circulation time. Moreover, the combination of the unique intrinsic properties of nanomaterials with radionuclides can construct multifunctional carriers, which achieve mutual complementarity. In this paper, we summarize the research progress of nanomaterials in tumor radionuclide therapy (including radionuclide therapy, radionuclide/chemo therapy, radionuclide/immuno therapy, radionuclide/photothermal therapy, radionuclide/photodynamic therapy, and radionuclide/chemodynamic therapy) and prospect the future development and challenges of nano-radiopharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.